Drugs / rMBCG
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06800963 | Oct 2025 → Feb 2028 expected | non-invasive bladder urothelial carcinoma | ImmunityBio, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rMBCG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06800963 ↗ |
| Known as | Recombinant Mycobacterium Bacillus Calmette-Guérin (BCG) | “This is a phase 1/2, open-label, multicenter study of intravesical Recombinant Mycobacterium Bacillus Calmette-Guérin (BCG) in participants with Non-muscle invasive bladder...” NCT06800963 ↗ |
| Route | Other | “via a urinary catheter in the bladder (ie, intravesical administration)” NCT06800963 ↗ |